



# A Special Report on Changing Trends in Preventive Stroke/Cardiovascular Risk Assessment Via B-Mode Ultrasonography

Ankush Jamthikar<sup>1</sup> · Deep Gupta<sup>1</sup> · Narendra N. Khanna<sup>2</sup> · Tadashi Araki<sup>3</sup> · Luca Saba<sup>4</sup> · Andrew Nicolaides<sup>5</sup> · Aditya Sharma<sup>6</sup> · Tomaz Omerzu<sup>7</sup> · Harman S. Suri<sup>8</sup> · Ajay Gupta<sup>9</sup> · Sophie Mavrogeni<sup>10</sup> · Monika Turk<sup>7</sup> · John R. Laird<sup>11</sup> · Athanasios Protogerou<sup>12</sup> · Petros P. Sfikakis<sup>13</sup> · George D. Kitas<sup>14</sup> · Vijay Viswanathan<sup>15</sup> · Gyan Pareek<sup>16</sup> · Martin Miner<sup>17</sup> · Jasjit S. Suri<sup>18</sup>

© Springer Science+Business Media, LLC, part of Springer Nature 2019

## Abstract

**Purpose of Review** Cardiovascular disease (CVD) and stroke risk assessment have been largely based on the success of traditional statistically derived risk calculators such as Pooled Cohort Risk Score or Framingham Risk Score. However, over the last decade, automated computational paradigms such as machine learning (ML) and deep learning (DL) techniques have penetrated into a variety of medical domains including CVD/stroke risk assessment. This review is mainly focused on the changing trends in CVD/stroke risk assessment and its stratification from statistical-based models to ML-based paradigms using non-invasive carotid ultrasonography.

**Recent Findings** In this review, ML-based strategies are categorized into two types: non-image (or conventional ML-based) and image-based (or integrated ML-based). The success of conventional (non-image-based) ML-based algorithms lies in the different data-driven patterns or features which are used to train the ML systems. Typically these features are the patients' demographics, serum biomarkers, and multiple clinical parameters. The integrated (image-based) ML-based algorithms integrate the features derived from the ultrasound scans of the arterial walls (such as morphological measurements) with conventional risk factors in ML frameworks.

**Summary** Even though the review covers ML-based system designs for carotid and coronary ultrasonography, the main focus of the review is on CVD/stroke risk scores based on carotid ultrasound. There are two key conclusions from this review: (i) fusion of

---

This article is part of the Topical Collection on *Cardiovascular Disease and Stroke*

---

✉ Jasjit S. Suri  
jasjit.suri@atheropoint.com

<sup>1</sup> Department of ECE, Visvesvaraya National Institute of Technology, Nagpur, Maharashtra, India

<sup>2</sup> Department of Cardiology, Indraprastha APOLLO Hospitals, New Delhi, India

<sup>3</sup> Division of Cardiovascular Medicine, Toho University, Tokyo, Japan

<sup>4</sup> Department of Radiology, University of Cagliari, Cagliari, Italy

<sup>5</sup> Vascular Screening and Diagnostic Centre, University of Cyprus, Nicosia, Cyprus

<sup>6</sup> Cardiovascular Medicine, University of Virginia, Charlottesville, VA, USA

<sup>7</sup> Department of Neurology, University Medical Centre Maribor, Maribor, Slovenia

<sup>8</sup> Brown University, Providence, RI, USA

<sup>9</sup> Department of Radiology, Cornell Medical Center, New York, NY, USA

<sup>10</sup> Cardiology Clinic, Onassis Cardiac Surgery Center, Athens, Greece

<sup>11</sup> Heart and Vascular Institute, Adventist Health St. Helena, St. Helena, CA, USA

<sup>12</sup> Department of Cardiovascular Prevention & Research Unit Clinic & Laboratory of Pathophysiology, National and Kapodistrian University of Athens, Athens, Greece

<sup>13</sup> Rheumatology Unit, National Kapodistrian University of Athens, Athens, Greece

<sup>14</sup> R&D Academic Affairs, Dudley Group NHS Foundation Trust, Dudley, UK

<sup>15</sup> MV Hospital for Diabetes and Professor M Viswanathan Diabetes Research Centre, Chennai, India

<sup>16</sup> Minimally Invasive Urology Institute, Brown University, Providence, RI, USA

<sup>17</sup> Men's Health Center, Miriam Hospital Providence, Providence, RI, USA

<sup>18</sup> Stroke Monitoring and Diagnostic Division, AtheroPoint™, Roseville, CA 95661, USA

image-based features with conventional cardiovascular risk factors can lead to more accurate CVD/stroke risk stratification; (ii) the ability to handle multiple sources of information in big data framework using artificial intelligence-based paradigms (such as ML and DL) is likely to be the future in preventive CVD/stroke risk assessment.

**Keywords** Atherosclerosis · Carotid artery · Coronary artery · Stroke risk · Cardiovascular risk · Machine learning · Deep learning · Conventional systems · Integrated systems

## Introduction


In 2017, cardiovascular diseases (CVD) such as heart attack and stroke killed 17.9 million people (31% of global mortality) around the world [1]. Plaque buildup in carotid and coronary arteries (also called as atherosclerotic disease, see Fig. 1) is one of the major cause of such mortalities. Recent findings indicate that traditional risk factors including ethnicity, age, hyperlipidemia, hypertension, diabetes mellitus, smoking, family history of coronary artery diseases, obesity, and physical inactivity are responsible for a majority of cardiovascular (CV) mortalities [2, 3, 4]. Optimal management of CVD requires the following: (i) the in-depth understanding of various CV risk factors that are associated with the disease; (ii) early prediction of the CVD/stroke risk; and (iii) the initiation of preventive methods such as usage of statins to treat the disease prior to the occurrence of the vascular events.

In the last decade, various efforts were made for the optimal management of CVD/stroke by developing computational risk prediction models [5–15]. All such clinically well-established risk prediction models provide long-term risk prediction by taking into consideration the traditional and non-

traditional CV risk factors to create a tool for primary prevention. However, the majority of these risks prediction models are not generalizable due to specific cohort characteristics from which they were derived. As a result, these models either underestimate or overestimate the CVD risk when applied to a cohort with a different baseline risk profile [16–18]. Another important fact about traditional risk scores is that they do not incorporate the morphological variations of the atherosclerotic plaque detectable during imaging tests. Such image-based data is increasingly being recognized as a key biomarker responsible for the onset of the stroke or CV events [19–21].

Recent advancements in imaging techniques have facilitated a clear visualization of the atherosclerotic plaque morphology and the measurement of several image-based phenotypes. The visualization can be in different shapes and sizes depending upon the nature of imaging (cross-sectional vs. longitudinal). For example, imaging coronary artery using intravascular ultrasound (IVUS) provides the cross-sectional images of plaque morphology, while imaging carotid artery using B-mode ultrasound provides longitudinal images of plaque morphology. In general, some commonly used image-based phenotypes are based on (i) wall area (using B-mode ultrasound)

**Fig. 1** General schematic diagram depicting the role of non-invasive carotid ultrasound and intravascular ultrasound in the detection of vascular atherosclerosis (Courtesy of AtheroPoint™, Roseville, CA, USA and Reproduced with permission from Elsevier)



and volume of calcium (using IVUS) [22, 23], (ii) thickness of microstructural high-risk atherosclerotic plaque components such as thin-capped fibroatheroma (using intravascular optical coherence tomography) [24, 25], (iii) coronary artery calcium scores (using cardiac computed tomography or CT) [26], (iv) identification of calcified and non-calcified plaques using coronary computed tomography [27], and (v) carotid image features which include carotid intima-media thickness (cIMT), carotid plaque (CP) area [28, 29], wall variability [30], and composite risk scores [31]. In this review, we will focus on the carotid and coronary ultrasound image-based risk factors using advanced machine learning (ML) algorithms.

Carotid arteries are considered to be a surrogate indicator of CVD risk. This is because both carotid and coronary arteries have a similar genetic makeup, and both can be affected by the atherosclerotic plaque buildup in their vascular beds as depicted in Fig. 1. In the last two decades, the use of B-mode carotid ultrasound imaging modality for the assessment of atherosclerotic vascular diseases has gained popularity due to its non-invasive, ergonomic, and economic nature [32–38]. cIMT and CP extracted from B-mode carotid ultrasound images are considered to be the two most vital image-based risk factors of myocardial infarction and stroke events [19, 20, 39–41]. Several longitudinal studies have reported the use of cIMT and CP for the prevention of vascular disease [33–37]. This has resulted in the framing of guidelines that report the use of cIMT and CP for the CVD risk assessment [28, 42–44]. Carotid ultrasound image-based phenotypes are also associated with conventional cardiovascular risk factors (CCVRF) such as age, increased blood pressure, hyperlipidemia, diabetes mellitus, smoking, and body mass index. Nambi et al. [28] reported an improvement in the CVD risk prediction when both the cIMT and CP were taken into consideration along with the traditional risk factors. Thus, scanning the carotid arteries using non-invasive B-mode ultrasound can improve CVD and stroke risk assessment.


At present, more than 100 CVD risk prediction models are available but the selection of the most suitable risk prediction model is still being debated [45]. The majority of the conventional risk prediction models are based on traditional statistical methods such as multivariate linear regression, logistic regression, and Cox regression models [5, 9, 12, 13, 46]. Such methods allow the inclusion of a small number of risk factors (or covariates) in the risk model. Furthermore, all such models are good at indicating an association of risk predictors with CVD [5, 9, 12, 13, 46]. However, in the case of CV or stroke event prediction, they provide little generalizable benefit [47] because the statistically derived risk prediction models are based on the cohort characteristics which may vary from one cohort to another. Furthermore, local patterns in the clinical, demographics-based, and traditional risk factors from different cohorts are prone to noise (such as data fluctuations or missing values or sudden large deviations) and biases which

are not accurately captured by such risk predicting models [47]. Lastly, the missing piece of the model is the exclusion of image-based morphological characteristics. This makes the overall risk evaluation systems weak and unreliable. Thus, in order to provide accurate and reliable CVD/stroke risk prediction, it is essential to look beyond the scope of traditional statistically derived risk calculators [47].

Innovations in intelligence-based paradigms such as ML and deep learning (DL) have performed exceptionally well in almost all medical domains [48–52]. The roots of ML systems lie in big data analytics. The term big data indicates the large storage of datasets with multiple clinical demographics (taken at the same time such as coronary, carotid, renal, etc.) collected from multiple sources. In Fig. 2, big data has been represented as a collection of data-driven risk factors from multiple sources that include the patients' demographics, conventional risk factors such as diabetes mellitus, hyperlipidemia, smoking, hypertension, and the image-based phenotypes. Machine learning algorithms can make use of all these stored data and try to analyze different patterns that represent the data. ML systems learn to recognize the different patterns in the dataset and produce CVD and stroke prevention prediction models. ML-based models follow the data-driven approach, meaning that these models automatically learn their coefficients from the different global and local patterns available in the big data which may vary among different population cohorts. In recent years, studies have shown the potential of various ML techniques in CV and stroke risk prediction [53, 54••]. Similarly, ML algorithms have also been adopted for stroke risk assessment by characterizing carotid atherosclerotic plaques tissues from the B-mode ultrasound images [55, 56, 57•, 58•, 59, 60]. In comparison to traditional risk calculators, recent findings indicate better performance of ML techniques for accurate CVD risk estimation [54••]. Kakadiaris et al. [61••] recently published a 13-year follow-up study to show that an ML-based risk calculator outperformed the well-established pooled cohort risk score (PCRS), a risk calculator which is based on the recent guidelines of American Heart Association and American College of Cardiology (also called as ACC/AHA risk score or atherosclerosis CVD risk score).

The breakthrough results presented by Weng et al. [54••] and Kakadiaris et al. [61••] have started a new quest to compare the automated ML (also broadly referred to as artificial intelligence) risk prediction models to well-established conventional risk calculators. Motivated by these results, this review provides a more informative understanding of the different ML techniques and various other approaches utilized for CVD and stroke risk prediction. The main focus of this review is to investigate the various ML-based systems used for CVD/stroke risk assessment in particular to carotid and coronary atherosclerosis diseases and more specifically using ultrasonography. Furthermore, the role of different conventional and image-based features has also been discussed in this review.

**Fig. 2** Machine learning and deep learning system framework using big data



## Article Search Strategy

This review is the outcome of rigorous searches on PubMed, Cochrane Library, and Web of Science to obtain the articles which were published in high impact factor peer-reviewed journals. We took a search window spanning the most recent 10 years for selecting the matching publications for this review. The keywords used for searching articles in the most recent 10 years were as follows: “Cardiovascular Risk Assessment,” “Stroke Risk Assessment,” “10-year CVD risk calculator,” “Machine learning-based CVD risk calculator,” “carotid ultrasound-based stroke risk,” “automated CVD risk estimation,” “carotid atherosclerotic plaque and machine learning,” “coronary atherosclerotic risk assessment.” Furthermore, a list of references from shortlisted research publications was also shortlisted for this review. Topics discussed in this article were initially discussed with experts in the field of cardiology, neurology, biomedical imaging, computer science, and artificial intelligence covering ML- and DL-based risk assessment.

## Risk Assessment Using Traditional Methods

Traditional methods of CVD and stroke risk assessment are based upon the statistically derived risk calculators [5–7, 14, 62–66]. Nearly all of these conventional risk prediction models provide the risk estimation based on conventional regression techniques [67]. For example, the well-established Framingham Risk Score (FRS) [5], the United Kingdom Prospective Diabetes Study (UKPDS56) [14], the Reynolds Risk Score (RRS) [9], the NIPPON score [14], and the Pooled Cohort Risk Score [6] were all developed by using a Cox regression model (i.e., a proportional hazard model). Similarly, the Systematic Coronary Risk Evaluation (SCORE) calculator adapted the Weibull regression model [7]. As discussed in the “Introduction” section, such statistical models are well suited when the application is to find the association between risk predictors (so-called risk factors or

covariates) and the outcome of interest. Recently, Goldstein et al. [47] pointed out three major challenges associated with these regression-based risk prediction models. (i) These models do not represent the true non-linear relationships between risk predictors and the outcome of interest. This means the regression-based models assume the predictor is linearly associated with the clinical outcome. (ii) The risk predictors are sometimes inter-dependent on each other. Thus, their effect on the outcome may not truly be captured by such regression-based models. (iii) When the number of risk predictors obtained from the dataset is large, then it becomes difficult to decide which risk factors to include in the regression-based models. This may be because of the small but significant associations between some of the risk predictors and the outcome of interest, which may otherwise make the model unstable. More research is required to understand and validate these calculators and further to explain their behaviors with the diverse risk factors. Before we dwell into ML-based CVD/Stroke risk calculators, we will briefly review ML fundamentals and the architectures.

## Fundamentals of Machine Learning

### Types of Machine Learning Techniques

Primarily, ML-based models are divided into three categories (Fig. 2, labeled as “Learning methods”): (i) *Supervised* learning and (ii) *Unsupervised* learning, and (iii) *Reinforcement* learning. In *Supervised* learning, the predefined binary labels (high-risk or low-risk; *event* or *non-event*) are obtained from the physicians or from the longitudinal trials as inputs that are used to train the ML system on how to correctly predict the risk outcome. For example, an automated cardiovascular event prediction system is usually provided with predefined labels corresponding to an *event* or *no-event* category [53, 68]. In risk assessment systems, the input labels (or response variable) can be obtained from the expert physicians or from results of the longitudinal follow-up studies, or by designing



a response variable using a combination of risk factors. The *Unsupervised* learning ML system performs risk stratification without any prior user inputs or labels by identifying and then clustering similar local patterns from the source data [69]. Once trained, each of the clusters corresponds to the one output category; for instance, in the above example, the output clusters can either be an *event* or *no-event* category. *Reinforcement learning* is another ML technique which provides its predictions based on rewards. Reinforcement learning is widely adapted in gaming and robotic applications [70]. This review is focused on the supervised ML-based algorithms used in CVD/stroke risk assessment adapting ultrasonography.

### General Framework of Machine Learning


Machine learning combines the knowledge of computer science and mathematical and statistical models to self-train the systems to provide the desired outcome. The outcome can be the prediction of absolute real numbers or it can be a classification of the input data into the set of desired output classes. Figure 3 shows the generalized ML-based framework that is divided into five stages and discussed below in brief in the following order: (i) feature engineering, (ii) data partitioning, (iii) model building (or offline system), (iv) prediction (or online system), and (v) performance evaluation.

### Feature Engineering: Extraction and Selection

Feature engineering is the most crucial part of any ML-based system that helps in interpreting the input dataset. In CVD/

stroke risk assessment, these features can be either CCVRFs such as patients’ demographics, serum biomarkers, and clinical variable or image-based phenotypes such as grayscale features [59, 71, 72], texture-based features [73], discrete wavelet transformed-based features [74], Riesz-based features [75], higher order spectra (HOS)-based features [76, 77], fractal features, and local binary patterns [78]. Quantitative carotid wall-based features extracted from B-mode ultrasound images such as cIMT and CP are also considered to be reliable for CVD/stroke risk assessment. According to the consensus report of the American Society of Echocardiography, cIMT measurements are generally performed in 1 cm region of common carotid artery at a proximal distance of 1 cm from the bulb [42]. However, studies have shown that measuring the distance between lumen-intima (LI) and media-adventitia (MA) throughout the length of the carotid artery including CP thickness provides an additional benefit in the risk assessment [79, 80]. AtheroEdge™ (AtheroPoint™, Roseville, CA, USA) has exclusively published and established a system which can measure fully and automatically cIMT throughout the carotid artery in just a few seconds [81]. The system outputs image-based phenotypes include average cIMT (cIMTave), maximum cIMT (cIMTmax), minimum cIMT (cIMTmin), variability in cIMT (cIMTV), and morphologic total plaque area (mTPA). The system underwent inter- and intra-operator variability analysis recently [82–84]. Under wall-based features, one can also measure lumen diameter (LD) [84], stenosis severity index (SSI) [85, 86], and inter-adventitial diameter (IAD) [87]. Excellent inter- and intra-operator variability for LD and IAD was recently shown in the AtheroEdge™ model (deep learning for LD) [88].

**Fig. 3** The architecture of the ML algorithm showing four stages



The CCVRFs and image-based phenotypes provide a detailed understanding of the severity of CVD/stroke disease and can be used to train the ML-based systems. Recently, Khanna et al. [89] presented a study that estimated the 10-year CUS image-based phenotypes by integrating the five types current image-based phenotypes (cIMTave, cIMTmax, cIMTmin, IMTV, mTPA) with conventional risk factors. Such 10-year features can also be used in the ML-based system to provide CVD/stroke risk stratification.

Besides feature extraction, dominant feature selection is another important technique that captures the most relevant features and then trains the ML systems. However, feature selection can only benefit the ML system if a large number of features are captured from the input data. Some commonly used feature selection methods are random forest, logistic regression, mutual information, principal component analysis, analysis of variance, and Fisher discriminant ratio [90, 91].

### Data Partitioning

Data partitioning involves dividing the input data set into two parts: (a) training dataset and (b) testing dataset. Multiple protocols exist for performing this data partitioning task. The most common protocol is 10-fold cross-validation, where the input dataset set is divided into ten equal parts, and at any time, nine parts are used for training the ML-based system while the remaining one part is used for validating the predictions of the system. This is also termed as K10 protocol where 10 indicate the number of total partitions designed during ML-based training model (typically using 80% of the dataset for training). The similar well-known data partitioning protocols are K2 protocol, K3 protocol, K4 protocol, and Jack Knife (also called as leave-one-out) cross-validation protocols, depending upon the percentage of data used for training as 50, 66, 75, and 99%, respectively. Since in a leave-one-out cross-validation protocol, N-1 samples are used for training and one sample is used for testing, it is generally adopted when the sample size is relatively small [92].

### Training Model Design

Training model design involves teaching the ML-based algorithm to learn from the input training features over several iterations. Since this review is focused on supervised ML systems, predefined ground truth labels are required during the training phase, which in turn generates the offline coefficients. During each of the training iteration, ML-based algorithms provide the output predictions and compute the probable loss (also called an error) by comparing against the supplied labels (response variable). Based on the loss value, the internal coefficients of the model (so-called as hyperparameters) are adjusted. After updating the hyperparameters, ML-based algorithms will be again trained on the input features. The process

of updating hyperparameters continues until the loss is minimum (we also call this instance, when the machine is able to split or partition well and the plane of separation is the hyper-plane). This is so-called a state in which the ML model is considered to be trained.

### Prediction or Testing Model

In the prediction or testing phase, the optimized coefficients from the trained model (training parameters) are used to transform the test features (derived from the test data) into the output or predicted class. This is also called an online process since this model accepts training parameters from the offline system and transforms the test features from the online system. In cross-validation protocols, the test data is a dataset completely different from the training data. Typically a good artificial intelligence model in risk stratification is a one which trains the machine only one time while the predictions can be done on several types of test data sets. More sophisticated machines are required to train and test on different types of datasets.

### Performance Evaluation of Machine Learning Systems

Performance evaluation (PE) metrics are generally used to test the ability of ML systems to accurately predict the risk categories of patients [93]. In the PE model, the predicted class labels of the test patient are computed using the prediction model and compared against the corresponding ground truth label, which is then used by the performance evaluation metric. The choice of a PE metric is of utmost importance because it indicates the degree to which the trained and tested model is accomplishing the desired outcomes. Area-under-the-curve (AUC) derived from receiver operating characteristic analysis is a widely adopted PE metric in medical applications. It indicates the overall performance of the system in terms of sensitivity and specificity (see Appendix). Besides the classification accuracy, Brier score [94] and concordance index [95] are commonly used PE metrics in CV risk assessment [12, 53, 96].

### ML-Based Algorithms

In general, classification and regression are the two primary tasks in ML-based algorithms. Almost all the ML-based algorithms are capable of performing both of these two tasks. Classification basically categorizes the input data into one of the predefined labels or outcomes. For example, in a CVD/stroke event prediction task, the input features are generally classified into either “*Event*” or “*No-Event*” category. Regression-based ML algorithms are generally used for predictions of some real-valued output. For example, in a CVD/stroke risk estimation task, regression-based ML algorithms

provide the real-valued percentage risk between 0 and 100%. This review is mainly focused on the ML-based application consisting of classification task. The most common ML algorithms used in CVD risk assessment are support vector machine (SVM) [97], artificial neural networks (ANN) [98], linear and logistic regression [54••], and tree-based algorithms such as random forest (RF) and decision tree (DT) [54••]. Another category of ML is ensemble learning techniques, in which the outcomes of all ML techniques can be combined to train the ML model to increase the accuracy of risk prediction. In Tables 1, 2, and 3, we have compared multiple studies presented on ML-based CVD/stroke risk assessment. One important observation is that most of the studies have utilized the SVM as a classifier during training and testing of classification tasks.

### Risk Assessment in Machine Learning Framework

In last decade, various efforts were made to perform the ML-based CV risk stratification using imaging modalities such as carotid CT [74], coronary CT angiography [107], single photon emission CT (SPECT) [108], echocardiography [71, 109], magnetic resonance imaging [110], and optical coherence tomography [25]. However, since this review is largely focused on the ML-based CV risk stratification using ultrasound imaging, the discussion on other imaging modalities is considered to be out-of-scope for this review. This section covers various efforts made in the direction of ML-based CV risk stratification using ultrasound imaging (of both coronary and carotid arteries).

### Image-Based Stroke Risk Assessment Using Machine Learning

Deposition of atherosclerotic plaque leading to restriction of blood flow in the carotid and coronary arteries leads to cerebrovascular (ischemic stroke) and cardiovascular (myocardial infarction) events [111, 112]. In recent years, ML-based algorithms have been widely adopted for stroke risk assessment using non-invasive imaging modalities such as carotid ultrasound [56, 57•, 58•, 59, 60]. Carotid atherosclerotic plaque burden is a crucial biomarker for stroke events and can be readily assessed using imaging tests [20, 113]. The appearance of CP in the B-mode ultrasound image (brighter/hyperechoic/echogenic or darker/hypoechoic/echolucent) adds valuable information about the risk profile of a patient [114]. It has been shown that echolucent (darker) atherosclerotic plaque (darker plaque) is a potential indicator for stroke events [115, 116]. It has also been shown that the effect of this echolucent plaque is more pronounced in patients with diabetes [117]. Similarly, echogenic (brighter) plaque due to the presence of calcium

within a plaque [118, 119] may be a marker of less vulnerable/low-risk plaque compared to the echolucent plaque. Identification of both of these plaque phenotypes is a crucial step in stroke risk assessment and can possibly be useful in treatments of stenting or endarterectomy [55, 56, 60, 120]. This decision is clearly a classification task, for which the ML-based systems are well suited. In the last decade, multiple efforts were made to automatically classify CP phenotypes [55, 56, 57•, 60].

In 2010, Acharya et al. [55] presented a study that classified carotid atherosclerotic plaque using the supervised ML-based algorithm such as SVM and AdaBoost classifier. Texture patterns captured using carotid ultrasound images along with the statistical features (mean and standard deviation) were used to train these ML systems. Authors reported 82.4% classification accuracy using SVM-based classifier. In 2013, the same group (Acharya et al. [56]) again classified CP phenotypes by considering the combination of discrete wavelet transform (DWT), HOS, and texture features. With the addition of both the DWT and HOS features, classification accuracy increased to 91.7%. Other similar studies of stroke risk assessment using carotid plaque phenotypes in ML-based algorithms are presented in Tables 1, 2, and 3.

### Cardiovascular Diseases Risk Assessment Using Machine Learning

In the last few years, ML-based algorithms have widely penetrated into the domain of primary CVD risk assessment, particularly in (i) coronary artery disease using characterization of coronary atherosclerotic plaque tissues, (ii) CVD risk using coronary calcium score, (iii) coronary artery disease based on conventional risk factors, (iv) overall CVD risk, and (v) prediction of CV events. Risk assessment using ML in each of these different applications requires the data-specific patterns to train the ML model, and then to transform the trained knowledge to predict the risk on the test data. These patterns can be derived from the CCVRFs, serum biomarkers, patients' demographics, imaging modalities or from the combination of these. In the last decade, multiple studies have explored the potential advantages of using different combinations of features for ML-based cardiovascular risk assessment [53, 71, 73, 92].

Using IVUS coronary imaging modality, Araki et al. [92] demonstrated the CAD risk stratification of 15 Japanese patients using 56 grayscale features. The IVUS image-based gray features were captured from the region between inner elastic lamina and external elastic lamina of the coronary wall. The IVUS examinations scanned the coronary arteries including the left and right anterior descending, left circumflex, and left main coronary artery. Overall, when using the SVM-based classifier, the ML classification accuracy for this automated system was 94.95%. This improvement is likely due to inclusion of the following: (i) more dominant features along with

**Table 1** Machine learning-based CVD/stroke risk stratification in both carotid and coronary artery

C1 C2	C3	C4	C5	C6	C8	C9	C10	C11	C12	C13	C14	
SN	Authors	AT (modality)	Features types	TF	Feature selection	Classifier type	Ground truth	N*	TI	Training protocol	Performance evaluation	Benchmarking
R1	Acharya et al. [56] (2011)	Carotid (CUS)	DWT, HOS, & texture features	7	Statistical test	SVM	Labels from physicians	99	112	K3	Se (97%), Sp (80%), ACC (91.7%)AUC (0.885)	-
R2	Acharya et al. [57] (2011)	Carotid (CUS)	DWT features	54	Statistical test	SVM	Labels from physicians	-	346	-	ACC (83.7%)	-
R3	Acharya et al. [60] (2012)	Carotid (CUS)	Texture	8	Statistical test	SVM	Risk labels from physicians	71	346	-	ACC (83%)	Against kNN, RBPNN
R4	Acharya et al. [59] (2013)	Carotid (CUS)	Grayscale features	17	Statistical test	SVM, GMM, RBPNN, DT, kNN, NBC, FC	Labels from physicians	445	492	K3	DBI+ACC (93.1%)DBI: ACC (85.3%)	-
R5	Acharya et al. [99] (2014)	Carotid(CUS)	Phenotypes & HOS features	7	Statistical test	SVM, RBPNN, kNN, DT	Labels from physicians	59	118	K 10	ACC (99.1%)	-
R6	Karacou et al. [100] (2012)	Carotid (CUS)	Image-based texture	27	Statistical test	SVM, LR	Follow-up data labels	108	-	-	ACC (77%)	-
R7	Gastouniotti et al. [101] (2015)	Carotid (CUS)	Kinematics features	1236	FDR, WRS, PCA	SVM	Follow-up data labels	56	4200	-	ACC (88%)	Against kNN, PNN, DT, DA
R8	Araki et al. [92] (2016)	Coronary (IVUS)	Grayscale features	56	PCA	SVM	cIMT	19	4004	-	ACC (94.95%)AUC (0.98)	-

CUS carotid ultrasound, LR logistic regression, SVM support vector machine, Se sensitivity, Sp specificity, ACC accuracy, DWT discrete wavelet transform, kNN K-Nearest Neighbor, RBPNN Radial Basis Probabilistic Neural Network, GMM Gaussian Mixture Model, DT decision tree, NBC Naive Bays Classifier, FC Fuzzy Classifier, DB database, HOS higher order spectra, LBP local binary pattern, FDR Fisher discriminant ratio, WRS Wilcoxon Rank-Sum, PCA principal component analysis, DA discriminant analysis

feature selection methods such as principal component analysis (PCA) or Fisher discriminant analysis; and (ii) plaque motion analysis. Banchhor et al. [73] recently extended Araki's [92] work to include coronary wall parameters. In total, 65 carotid and coronary wall-based features were used to perform the ML-based coronary artery disease risk assessment. Using the PCA-based features selection approach in conjunction with an SVM-based classifier, the authors reported a classification accuracy of 91.28% with AUC of 0.91. Both of these studies (Araki et al. [92] and Banchhor et al. [73]) indicated the link between coronary and carotid atherosclerosis by considering the cIMT and plaque burden as the gold standard to perform the supervised CVD risk stratification.

Risk assessment based on longitudinal trials or follow-up studies is generally considered to be accurate and widely adopted in clinical practice. Proportional hazard models and risk calculators are the conventional tools for CVD risk assessment [5–14]. However, a very recently published study by Ambale-Venkatesh et al. [53] demonstrated that the ML-based algorithms are more accurate and better compared to traditional proportional hazard models for CVD risk assessment. Authors included the participants from the well-known Multi-Ethnic Study for Atherosclerosis (MESA), a 12-year longitudinal cohort study. A total of 735 CV risk predictors or features were extracted from diverse sources such as patients' demographics, traditional risk factors, imaging modalities, questionnaires, and laboratory biomarkers. Authors reported an overall C-index of 0.81 and a Brier score of 0.083 using the random forest-based classifier. The authors also benchmarked their results against the traditional CV risk assessment tools such as FRS and PCRS. Compared to these traditional risk scores, authors indicated an improvement C-index by ~ 10% and decreased in Brier score by 10–25%.

Weng et al. [54] also presented a prospective study with 378,256 participants and reported better risk stratification using ML-based algorithms over the conventional statistically derived risk calculators. A total of 30 CCVRFs were used for training the ML-based algorithms. Authors compared the performance of four ML-based algorithms such as ANN, random forest, gradient boosting machine, and logistic regression. The study reported ANN to be the best classifier with an AUC of 0.76.

Kakadiaris et al. [61] reported the most recent study based on MESA participants that reported a superior performance of ML-based system compared to the PCRS-based calculator. The PCRS calculator was based on ACC/AHA guidelines that recommended the lipid-lowering statins to the patients whose risk was more than 7.5% to reduce the risk of ASCVD. Kakadiaris et al. [61] used the same PCRS but the statin eligibility threshold was chosen as 9.75%. This was mainly because of the 13-year follow-up nature of the MESA study, while the PCRS was based on 10-year follow-up dataset. The authors used the same nine CCVRFs that was used for



**Table 2** Machine learning-based CVD/stroke risk stratification in both carotid and coronary artery

C1 #SN	C2 Authors	C3 AT (modality)	C4 Features types	C5 TF	C6 Feature selection	C8 Classifier type	C9 Ground truth	C10 N*	C11 TI	C12 Training protocol	C13 PE	C14 Benchmarking
R1	Hu et al. [102] (2016)	NA	CCVRFs	41	Fisher	Naïve Bayes, MLP, RF	Follow-up data labels	382	382	K3	AUC (0.797), BS (0.085), ACC (98.57%)	-
R2	Narain et al. [103] (2016)	NA	CCVRFs	7	NA	QNN	Risk labels from physicians	682	NA	K3	-	Against FRs
R3	Umnikrishnan et al. [104] (2016)	NA	CCVRFs	9	NA	SVM	Follow-up data labels	2406	NA	K5	Se (68.2%), Sp (85.9%) AUC (0.71)	Against FRs
R4	Venkatesh et al. [53] (2017)	Coronary MRI Carotid US	CCVRFs, image phenotypes, & serum biomarkers	735	MDMST	RF, Cox, LASSO-cox, AIC-Cox backward regression	Follow-up data labels	6814	NA	K3	C-index (0.81), BS (0.083)	Against FRs & PCRS
R5	Zarkogianni et al. [105] (2017)	NA	CCVRFs	16	NA	HWNN & SOM	Follow-up data labels	560	NA	-	AUC (0.715), ACC (71.79%), BS (0.07)	Against UKPDS
R6	Banchhor et al. [73] (2017)	Coronary (IVUS)	Texture-based & wall-based features	65	PCA	SVM	Carotid plaque burden	22	4930	K10	ACC (91.28%) AUC (0.91)	-
R7	Araki et al. [68] (2017)	Carotid (CUS)	Image-based texture features	16	Statistical test	SVM	LD-based risk labels	204	407	K5, K10, JK	ACC (NW: 95.08% & FW: 93.47%)	-
R8	Saba et al. [106] (2017)	Carotid (CUS)	Image-based texture	16	PCA	SVM	LD-based risk labels	204	407	K10	ACC (NW: 98.83% & FW: 98.55%)	-

CUS carotid ultrasound, SVM support vector machine, Se sensitivity, Sp specificity, ACC accuracy, PCA principal component analysis, MLP multilayer perceptron, RF random forest, BS Brier score, QNN quantum neural network, MDMST Minimal Depth of Maximal Subtree, SOM self-organization map

PCRS computation and demonstrated the better performance of ML-based SVM classifier (AUC = 0.92) compared to PCRS (AUC = 0.71). In this review, we have investigated some more studies that adapted ML-based algorithms for CVD risk assessment. A summary of all such studies along with their attributes is presented in Tables 1, 2, and 3.

### CVD/Stroke Risk Assessment Indices

Some investigators have recommended the use of the single index that quantifies the CVD/stroke risk [55, 56, 60, 71, 74, 121]. Acharya et al. [71] recommend the use of the single discriminative index called *HeartIndex* for assessing the risk of coronary artery disease (CAD). The *HeartIndex* was derived from the features to classify the echocardiography images into two risk classes: normal and CAD. In order to assess neurological risk, Pedro et al. [121] proposed the *enhanced activity index (EID)* that was based on the carotid artery plaque morphology and severity of carotid stenosis to classify the occurrence of ipsilateral ischemic symptoms. Acharya et al. [74] proposed the single values *Atheromatic™* index (from AtheroPoint™, Roseville, CA, USA) to identify two CP phenotypes: high vs. low risk. The design of the *Atheromatic™* index was based on the computed tomography image phenotypes which were derived from local binary patterns, wavelet transform, and the textures of the CP image. The same group [55] also proposed a *Symptomatic Asymptomatic Carotid Index (SACI)* based on the texture and statistical features derived from the carotid ultrasound image. The *SACI* index has also been tested in a carotid atherosclerotic plaque ultrasound-based tissue characterization study by computing the grayscale features in ML framework [56].

### Medical Implications of Machine Learning-Based Risk Assessment

Risk assessment systems are primarily aimed at identifying the risk profiles of patients and to stratify them into one of the several CVD risk classes (e.g., low-risk, moderate-risk, and high-risk classes). Risk stratification tools decide the need and strength of statins (i.e., the well-known lipid-lowering medications) such as atorvastatin, pravastatin, and simvastatin [122] and diabetes-controlling medications such as metformin [123].

Traditional statistically derived risk prediction models have been reported to either underestimate or overestimate the CVD risk [17, 18] and therefore have the unintended consequence of inappropriate medication prescription in some patients and inappropriate under-utilization in other patients, both of which have potential harmful side effects and outcomes. This also could increase the economic burden on the patients and healthcare systems. ML systems provide better risk assessment and supports in avoiding unnecessary over or

**Table 3** Machine learning-based CVD/stroke risk stratification in both carotid and coronary artery


C1 #SN	C2 Authors	C3 AT (modality)	C4 Features types	C5 TF	C6 Feature selection	C8 Classifier type	C9 Ground truth	C10 N*	C11 TI	C12 Training protocol	C13 Performance evaluation	C14 Benchmarking
R1	Weng et al. [54••] (2017)	-	CCVRFs	30	-	RF, LR, GBM, ANN	Follow-up data labels	378,256	-	K4	AUC: 0.764	Against PCRS
R2	Kakadiaris et al. [61••] (2018)	-	CCVRFs	9	-	SVM	Follow-up data labels	6459	-	K2	Se (86%), Sp (95%), AUC (0.92)	Against PCRS

LR logistic regression, SVM support vector machine, Se sensitivity, Sp specificity, RF random forest

under treatment [54••]. A recent follow-up study presented by Kakadiaris et al. [61••] investigated the statin eligibility for the patients using both (i) PCRS calculator based on ACC/AHA risk prediction guidelines and (ii) ML-based risk calculator. ACC/AHA model recommended statins for 46% of the patients while the ML-based risk calculator identified only 11.7% eligible for statin therapy.

## Deep Learning-Based Cardiovascular Risk Stratification

Deep learning is an extension of classical ANNs and efficient ML techniques to analyze medical images. It consists of multiple convolutional layers that allow extraction of more data-dependent patterns and thus, it helps in improving the accuracy of outcome prediction [124]. Convolutional neural network (CNN) is a DL algorithm which has gained large attention while analyzing medical images (Fig. 4). This is because CNN has the ability to extract a large number of image-based features compared to the handcrafted statistical features [125, 126]. In CNN algorithm, an input image gets convolved with a number of kernels which are responsible for the deck of feature extraction (convolution operation is shown by a green rectangle using kernel banks-magenta color). The features are selected using polling operation (shown by an inverted green triangle), where the meaningful features are selected. The coefficients of all these kernels are learned during the training process of CNN. A basic architecture of DL using CNN is as depicted in Fig. 4. There two challenges associated with the basic CNN architecture. (i) The basic architecture may suffer from overfitting due to the input data and thus, results in a reduction in risk stratification accuracy. (ii) The basic architecture may have a limited number of convolution layers. A larger number of convolutional layers extract more features from the input images and thus, provide the power to the DL system to separate the classes accurately. This, however, increases the complexity of the system. The two challenges can be solved (i) by including the dropout strategy in the basics model and (ii) by adding multiple inception layers in the basic model, respectively. The detailed version of DL using CNN has been depicted in Fig. 5. The details of dropout and inception layers are out of the scope of this review. However, their functionality has clearly been discussed in our previous paper [49]. The main advantage in CNN is its ability to extract the context-based features, and as a result does not require any prior information, as in *Supervised* ML, before training the system. Recently, Lekadir et al. [127] used CNN to automatically characterize the plaque tissues from carotid ultrasound images. A very recent set of studies by Biswas et al. [48, 88] used CNN to measure the cIMT and LD, respectively, based on CUS images. Although the focus of this review is on ultrasonography, it must be noted that DL techniques have also



**Fig. 4** An architectural diagram for the deep learning-based convolutional neural network algorithm (Courtesy of AtheroPoint™, Roseville, CA, USA and Reproduced with permission from Springer Nature)

been tried to perform risk assessment using different imaging modalities such as coronary CT angiography [128], optical coherence tomography [25], and MRI [110].

### Challenges in Machine Learning Design

There are some important key challenges while adapting ML techniques in medical domains especially in CVD/stroke risk assessment, including the following:

- *Black-Box Nature of the ML Techniques*

ML-based algorithms have proven their potential in providing robust and accurate solution almost in every medical domain including CVD/stroke risk assessment. However, it is somewhat challenging for clinical practitioners and physicians to adapt ML techniques in their clinical practice. This may be because of the so-called black box nature of ML algorithms [129] and lack of external validations. Unlike traditional


statistical-derived methods which are based on discrete clinical variables (e.g., age, blood pressure, diabetes), the internal working of ML algorithms is not easy to interpret for most physicians. This uncertainty about the logic of ML algorithm may cause some practitioners to be more reluctant to adopt this technology in clinical practice. Further, fewer studies have been published in respectable peer-reviewed journals that show (i) strong scientific validations, (ii) well-established gold standards, (iii) variation analysis of the data sets, and (iv) real-world ML clinical applications that can be adapted on daily basis.

- *Achieving Generalization of ML Models*

It is of paramount importance that the ML model must be generalizable [106]. This means the ML model designs must be tested on almost every relevant dataset including longitudinal follow-up datasets (or during prospective trials or retrospective data sets in which outcomes were recorded) with potentially different features. This makes the model more robust and clinically reliable.

- *Role of Transfer Learning*

Since conducting multiple clinical trials with large sample size to produce highly generalizable and reliable results is not economically viable, a ML technique known as transfer learning may be valuable. Furthermore, if an ML model is trained on a particular dataset with a unique set of features, then it also becomes practically impossible to collect the similar kind of features in multicenter trials due to its lengthy timely collection of data and soaring cost. This puts a limit generalization of ML systems. Transfer learning, therefore, provides the benefit of training on one set and application of transformed parameters on a different set.



**Fig. 5** Advanced CNN model by incorporating convolution, pooling, inception, softmax layers (Courtesy of AtheroPoint™, Roseville, CA, USA USA and Reproduced with permission from Elsevier)



- *Lack of Access to Data*

The biggest and the most important challenge for most ML-based data scientist and developers is the lack of access to the well-established patient and population-based datasets, such as MESA and ARIC. It is true that conducting such multicenter clinical trials is expensive, but further attempts at collaboration and improving access to such datasets are needed to validate these ML-based designs.

Because of these key challenges, medical practitioners are not ready to rely on ML techniques for clinical decision-making [93, 130]. It is of utmost importance for both medical practitioners and data scientists to come together and increase the interpretability of computationally complex ML techniques. In order to make the ML models generalizable, more funding sources should come together and conduct longitudinal multicenter clinical trials or observational studies that can benefit both data scientists and system developers to make more robust models.

## Conclusion

In this review, we reported the changing trend for CVD/stroke risk assessment, ranging from traditional statistically derived calculators to advanced ML-based risk assessment systems. ML-based algorithms show better performance compared to traditional methods. In this review, we found that the supervised machine technique such as SVM is the widely adapted ML-based algorithm for CVD risk assessment followed by random forest and ANN. Data-driven features are the most vital part of ML algorithms. Most of the risk assessment techniques (i.e., traditional and ML-based) commonly incorporated traditional CV features in their risk assessment model. For better risk assessment, the feature engineering domain needs to be explored more in the near future. Different image-based risk factors can be incorporated to improve automated risk assessment systems. Deep learning is the rapidly developing field for image analysis which extracts more robust features from images. Image phenotypes extracted using DL combined with CCVRFs can provide a better platform for CVD/stroke assessment. Verification and validation of the ML/DL systems is a crucial component for adopting the system designs in routine clinical practice. Finally, with the advancements in big data and artificial intelligence-based paradigms, we are likely to see more sophisticated CVD/stroke risk assessment tools in the future.

**Acknowledgments** Authors would like thank the editors and reviewers of the Current Reports of Atherosclerosis for giving valuable suggestions for improving the manuscript.

## Compliance with Ethical Standards

**Conflict of Interest** Ankush Jamthikar, Deep Gupta, Narendra N. Khanna, Tadashi Araki, Luca Saba, Andrew Nicolaides, Aditya Sharma, Tomaz Omerzu, Harman S. Suri, Ajay Gupta, Sophie Mavrogeni, Monika Turk, John R. Laird, Athanasios Protogerou, Petros P. Sfikakis, George D. Kitas, Vijay Viswanathan, Gyan Pareek, and Martin Miner declare no conflict of interest. Dr. Jasjit S Suri is affiliated to AtheroPoint, focused in the area of stroke and cardiovascular imaging.

**Human and Animal Rights and Informed Consent** This article does not contain any studies with human or animal subjects performed by any of the authors.

## Appendix: Performance Evaluation Parameters

Sensitivity and specificity are computed using true positive (TP), true negative (TN), false positive (FP), and false negative (FN). TP indicates the count for which predicted class labels matches with ground truth label for high-risk threshold point, FN is defined as the number of times the predicted class labels that are incorrectly classified as low-risk, FP is defined as the number of times the predicted class labels that are incorrectly classified as high-risk, and TN is defined as the number of times predicted class labels that are correctly matched with low-risk ground truth label. Sensitivity and specificity are mathematically represented as, Sensitivity =  $\frac{TP}{(TP+FN)}$  and Specificity =  $\frac{TN}{(TN+FP)}$ . Furthermore, the accuracy of risk stratification is mathematically represented as: Accuracy =  $\frac{TP+TN}{(TP+FN+FP+FN)}$ .

## References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
  - Of major importance
1. Cardiovascular diseases (CVDs): key facts by WHO 2016 [[http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))]. Accessed 1 Oct 2018.
  2. Rosengren A, Hawken S, Ōunpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004;364(9438):953–62.
  3. O'Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. *Lancet*. 2016;388(10046):761–75 **An important longitudinal study that associated the conventional risk factors with risk of stroke events.**



4. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet*. 2010;376(9735):112–23.
5. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. *Diabetes Care*. 2004;27(1):201–7.
6. Saba L, Molinari F, Meiburger K, et al. What is the correct distance measurement metric when measuring carotid ultrasound intima-media thickness automatically? *Int Angiol*. 2012;31(5):483–9.
7. Conroy R, Pyörälä K, Fitzgerald A, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J*. 2003;24(11):987–1003.
8. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. 2008;117(6):743–53.
9. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA*. 2007;297(6):611–9.
10. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). *Clin Sci*. 2001;101(6):671–9.
11. Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. *Stroke*. 2002;33(7):1776–81.
12. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. *BMJ*. 2017;357:j2099.
13. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014;63(25 Part B):2935–59.
14. Group NDR. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. *Circ J*. 2006;70(10):1249–55.
15. Nobel L, Mayo NE, Hanley J, Nadeau L, Daskalopoulou SS. MyRisk\_Stroke Calculator: a personalized stroke risk assessment tool for the general population. *J Clin Neurol*. 2014;10(1):1–9.
16. Bonek K, Głuszko P. Cardiovascular risk assessment in rheumatoid arthritis—controversies and the new approach. *Reumatologia*. 2016;54(3):128–35.
17. Arts E, Popa C, Den Broeder A, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. *Ann Rheum Dis*. 2014;74(4):668–74. [annrheumdis-2013-204024](#).
18. Garg N, Muduli SK, Kapoor A, et al. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. *Indian Heart J*. 2017;69(4):458–63.
19. Mathiesen Ellisiv B, Johnsen Stein H, Wilsgaard T, Bønaa Kaare H, Løchen M-L, Njølstad I. Carotid plaque area and intima-media thickness in prediction of first-ever ischemic stroke. *Stroke*. 2011;42(4):972–8.
20. Spence JD, Eliasziw M, DiCicco M, Hackam DG, Galil R, Lohmann T. Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. *Stroke*. 2002;33(12):2916–22.
21. Belcaro G, Nicolaidis AN, Ramaswami G, et al. Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVE study(1)). *Atherosclerosis*. 2001;156(2):379–87.
22. Garcia-Garcia HM, Costa MA, Serruys PW. Imaging of coronary atherosclerosis: intravascular ultrasound. *Eur Heart J*. 2010;31(20):2456–69.
23. Banchhor SK, Araki T, Londhe ND, et al. Five multiresolution-based calcium volume measurement techniques from coronary IVUS videos: a comparative approach. *Comput Methods Prog Biomed*. 2016;134:237–58.
24. Van Soest G, Regar E, Koljenovič S, et al. Atherosclerotic tissue characterization in vivo by optical coherence tomography attenuation imaging. *J Biomed Opt*. 2010;15(1):011105–9.
25. Boi A, Jamthikar AD, Saba L, et al. A survey on coronary atherosclerotic plaque tissue characterization in intravascular optical coherence tomography. *Curr Atheroscler Rep*. 2018;20(7):33.
26. Blaha MJ, Mortensen MB, Kianoush S, Tota-Maharaj R, Cainzos-Achirica M. Coronary artery calcium scoring: is it time for a change in methodology? *JACC Cardiovasc Imaging*. 2017;10(8):923–37.
27. Eckert J, Schmidt M, Magedanz A, Voigtländer T, Schmermund A. Coronary CT angiography in managing atherosclerosis. *Int J Mol Sci*. 2015;16(2):3740–56.
28. Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. *J Am Coll Cardiol*. 2010;55(15):1600–7.
29. Naqvi TZ, Lee M-S. Carotid intima-media thickness and plaque in cardiovascular risk assessment. *JACC Cardiovasc Imaging*. 2014;7(10):1025–38.
30. Saba L, Mallarini G, Sanfilippo R, Zeng G, Montisci R, Suri J. Intima media thickness variability (IMTV) and its association with cerebrovascular events: a novel marker of carotid atherosclerosis? *Cardiovasc Diagn Ther*. 2012;2(1):10–8.
31. Cuadrado-Godia E, Maniruzzaman M, Araki T, et al. Morphologic TPA (mTPA) and composite risk score for moderate carotid atherosclerotic plaque is strongly associated with HbA1c in diabetes cohort. *Comput Biol Med*. 2018;101:128–45.
32. Laine A, Sanches JM, Suri JS: Ultrasound imaging: advances and applications. Springer; 2012.
33. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. *Am J Epidemiol*. 1997;146(6):483–94.
34. O'leary DH, Polak JF, Kronmal RA, et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. *Stroke*. 1992;23(12):1752–60.
35. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. *Circulation*. 1997;96(5):1432–7.
36. Rosvall M, Janzon L, Berglund G, Engström G, Hedblad B. Incident coronary events and case fatality in relation to common carotid intima-media thickness. *J Intern Med*. 2005;257(5):430–7.
37. Lorenz MW, Schaefer C, Steinmetz H, Sitzer M. Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS). *Eur Heart J*. 2010;31(16):2041–8.
38. Khanna NN, Jamthikar AD, Gupta D, et al. Rheumatoid arthritis: atherosclerosis imaging and cardiovascular risk assessment using machine and deep learning-based tissue characterization. *Curr Atheroscler Rep*. 2019;21(2):7.
39. Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. *Arterioscler Thromb Vasc Biol*. 1991;11(5):1245–9.
40. Hirata T, Arai Y, Takayama M, Abe Y, Ohkuma K, Takebayashi T. Carotid plaque score and risk of cardiovascular mortality in the

- oldest old: results from the TOOTH study. *J Atheroscler Thromb.* 2018;25(1):55–64.
41. Park HW, Kim WH, Kim KH, et al. Carotid plaque is associated with increased cardiac mortality in patients with coronary artery disease. *Int J Cardiol.* 2013;166(3):658–63.
  42. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force endorsed by the Society for Vascular Medicine. *J Am Soc Echocardiogr.* 2008;21(2):93–111.
  43. Stein JH, Johnson HM. Carotid intima-media thickness, plaques, and cardiovascular disease risk: implications for preventive cardiology guidelines. In: *J Am Coll Cardiol.* 2010;55:1608–10.
  44. Polak JF, Pencina MJ, Pencina KM, O'Donnell CJ, Wolf PA, D'Agostino RB Sr. Carotid-wall intima-media thickness and cardiovascular events. *N Engl J Med.* 2011;365(3):213–21.
  45. Allan GM, Garrison S, McCormack J. Comparison of cardiovascular disease risk calculators. *Curr Opin Lipidol.* 2014;25(4):254–65.
  46. Conroy RM, on behalf of the Spg, Pyörälä K, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J.* 2003;24(11):987–1003.
  47. Goldstein BA, Navar AM, Carter RE. Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges. *Eur Heart J.* 2016;38(23):1805–14.
  48. Biswas M, Kuppili V, Araki T, et al. Deep learning strategy for accurate carotid intima-media thickness measurement: an ultrasound study on Japanese diabetic cohort. *Comput Biol Med.* 2018;98:100–17.
  49. Biswas M, Kuppili V, Edla DR, et al. Symtosis: a liver ultrasound tissue characterization and risk stratification in optimized deep learning paradigm. *Comput Methods Prog Biomed.* 2017;155:165–77.
  50. Lam C, Yi D, Guo M, Lindsey T. Automated detection of diabetic retinopathy using deep learning. *AMIA Jt Summits Transl Sci Proc.* 2017;2018:147–55.
  51. Heo J, Yoon J, Park HJ, Kim YD, Nam HS, Heo JH: Machine learning-based model can predict stroke outcome. In: *Am Heart Assoc* 2018.
  52. Erickson BJ, Korfiatis P, Akkus Z, Kline TL. Machine learning for medical imaging. *Radiographics.* 2017;37(2):505–15.
  53. Ambale-Venkatesh B, Wu CO, Liu K, et al. Cardiovascular event prediction by machine learning: the Multi-Ethnic Study of Atherosclerosis. *Circ Res.* 2017;121(9):1092–101 CIRCRESAHA. 117.311312.
  54. Weng SF, Reys J, Kai J, Garibaldi JM, Qureshi N. Can machine-learning improve cardiovascular risk prediction using routine clinical data? *PLoS One.* 2017;12(4):e0174944 **This study compared the ML-based risk stratification with conventional risk calculators.**
  55. Acharya RU, Faust O, Alvin APC, et al. Symptomatic vs. asymptomatic plaque classification in carotid ultrasound. *J Med Syst.* 2012;36(3):1861–71.
  56. Acharya UR, Faust O, Alvin A, et al. Understanding symptomatology of atherosclerotic plaque by image-based tissue characterization. *Comput Methods Prog Biomed.* 2013;110(1):66–75.
  57. Acharya UR, Faust O, Sree SV, et al. An accurate and generalized approach to plaque characterization in 346 carotid ultrasound scans. *IEEE Trans Instrum Meas.* 2012;61(4):1045–53 **This was an important study that performed the carotid atherosclerotic plaque characterization using ML approach.**
  58. Acharya UR, Krishnan MMR, Sree SV, et al. Plaque tissue characterization and classification in ultrasound carotid scans: a paradigm for vascular feature amalgamation. *IEEE Trans Instrum Meas.* 2013;62(2):392–400.
  59. Acharya UR, Mookiah MRK, Sree SV, et al. Atherosclerotic plaque tissue characterization in 2D ultrasound longitudinal carotid scans for automated classification: a paradigm for stroke risk assessment. *Med Biol Eng Comput.* 2013;51(5):513–23.
  60. Acharya UR, Sree SV, Krishnan MMR, et al. Atherosclerotic risk stratification strategy for carotid arteries using texture-based features. *Ultrasound Med Biol.* 2012;38(6):899–915.
  61. Kakadiaris IA, Vrigkas M, Yen AA, Kuznetsova T, Budoff M, Naghavi M. Machine learning outperforms ACC/AHA CVD risk calculator in MESA. *J Am Heart Assoc.* 2018;7(22):e009476 **This is the first of its kind study which have compared the machine learning-based risk calculator with ACC/AHA risk calculator. This article is very important to usage of ML in CVD risk assessment.**
  62. Ramachandran A, Snehalatha C. Current scenario of diabetes in India. *J Diab.* 2009;1(1):18–28.
  63. Gupta R, Rao RS, Misra A, Sharma SK. Recent trends in epidemiology of dyslipidemias in India. *Indian Heart J.* 2017;69(3):382–92.
  64. Anchala R, Kannuri NK, Pant H, et al. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. *J Hypertens.* 2014;32(6):1170–7.
  65. van der Meer IM, Iglesias del Sol A, Hak AE, Bots ML, Hofman A, Witteman JC. Risk factors for progression of atherosclerosis measured at multiple sites in the arterial tree: the Rotterdam Study. *Stroke.* 2003;34(10):2374–9.
  66. Øygarden H. Carotid intima-media thickness and prediction of cardiovascular disease. *J Am Heart Assoc.* 2017;6(1):e005313.
  67. Khanna NN, Jamthikar AD, Gupta D, et al. Performance evaluation of 10-year ultrasound image-based stroke/cardiovascular (CV) risk calculator by comparing against ten conventional CV risk calculators: a diabetic study. *Comput Biol Med.* 2019;105:125–43.
  68. Araki T, Jain PK, Suri HS, et al. Stroke risk stratification and its validation using ultrasonic echolucent carotid wall plaque morphology: a machine learning paradigm. *Comput Biol Med.* 2017;80:77–96.
  69. Bishop CM: *Pattern recognition and machine learning.* Springer 2006.
  70. Sutton RS, Barto AG: *Reinforcement learning: an introduction.* MIT press; 2018.
  71. Acharya UR, Sree SV, Krishnan MMR, et al. Automated classification of patients with coronary artery disease using grayscale features from left ventricle echocardiographic images. *Comput Methods Prog Biomed.* 2013;112(3):624–32.
  72. Shrivastava VK, Londhe ND, Sonawane RS, Suri JS. A novel and robust Bayesian approach for segmentation of psoriasis lesions and its risk stratification. *Comput Methods Prog Biomed.* 2017;150:9–22.
  73. Banchhor SK, Londhe ND, Araki T, et al. Wall-based measurement features provides an improved IVUS coronary artery risk assessment when fused with plaque texture-based features during machine learning paradigm. *Comput Biol Med.* 2017;91:198–212.
  74. Acharya U, Sree SV, Mookiah M, et al. Computed tomography carotid wall plaque characterization using a combination of discrete wavelet transform and texture features: a pilot study. *Proc Inst Mech Eng H J Eng Med.* 2013;227(6):643–54.
  75. Than JCM, Saba L, Noor NM, et al. Lung disease stratification using amalgamation of Riesz and Gabor transforms in machine learning framework. *Comput Biol Med.* 2017;89:197–211.
  76. Shrivastava VK, Londhe ND, Sonawane RS, Suri JS. Computer-aided diagnosis of psoriasis skin images with HOS, texture and

- color features: a first comparative study of its kind. *Comput Methods Prog Biomed.* 2016;126:98–109.
77. Pareek G, Acharya UR, Sree SV, et al. Prostate tissue characterization/classification in 144 patient population using wavelet and higher order spectra features from transrectal ultrasound images. *Technol Cancer Res Treat.* 2013;12(6):545–57.
  78. Acharya UR, Vinitha Sree S, Krishnan MM, Molinari F, Garberoglio R, Suri JS. Non-invasive automated 3D thyroid lesion classification in ultrasound: a class of ThyroScan systems. *Ultrasonics.* 2012;52(4):508–20.
  79. Molinari F, Meiburger KM, Saba L, et al. Automated carotid IMT measurement and its validation in low contrast ultrasound database of 885 patient Indian population epidemiological study: results of AtheroEdge® software. In: *Multi-modality atherosclerosis imaging and diagnosis.* Springer; 2014: 209–219.
  80. Molinari F, Zeng G, Suri JS. Intima-media thickness: setting a standard for a completely automated method of ultrasound measurement. *IEEE Trans Ultrason Ferroelectr Freq Control.* 2010;57(5):1112–24.
  81. Molinari F, Meiburger KM, Suri J: Automated high-performance cIMT measurement techniques using patented AtheroEdge™: a screening and home monitoring system. In: *Engineering in Medicine and Biology Society, EMBC, 2011 Annual International Conference of the IEEE: 2011.* IEEE; 2011: 6651–6654.
  82. Saba L, Banchhor SK, Araki T, et al. Intra-and inter-operator reproducibility of automated cloud-based carotid lumen diameter ultrasound measurement. *Indian Heart J.* 2018;70:649–64.
  83. Stein JH, Tattersall MC. Carotid intima-media thickness and cardiovascular disease risk prediction. *J Am Coll Cardiol.* 2014;63(21):2301–2.
  84. Saba L, Banchhor SK, Londhe ND, et al. Web-based accurate measurements of carotid lumen diameter and stenosis severity: an ultrasound-based clinical tool for stroke risk assessment during multicenter clinical trials. *Comput Biol Med.* 2017;91:306–17.
  85. Krishna Kumar P, Araki T, Rajan J, et al. Accurate lumen diameter measurement in curved vessels in carotid ultrasound: an iterative scale-space and spatial transformation approach. *Med Biol Eng Comput.* 2017;55(8):1415–34.
  86. Kumar PK, Araki T, Rajan J, Laird JR, Nicolaides A, Suri JS. State-of-the-art review on automated lumen and adventitial border delineation and its measurements in carotid ultrasound. *Comput Methods Prog Biomed.* 2018;163:155–68.
  87. Saba L, Araki T, Kumar PK, et al. Carotid inter-adventitial diameter is more strongly related to plaque score than lumen diameter: an automated tool for stroke analysis. *J Clin Ultrasound.* 2016;44(4):210–20.
  88. Muller K-R, Mika S, Ratsch G, Tsuda K, Scholkopf B. An introduction to kernel-based learning algorithms. *IEEE Trans Neural Netw.* 2001;12(2):181–201.
  89. Khanna NN, Jamthikar AD, Araki T, et al. Nonlinear model for the carotid artery disease 10-year risk prediction by fusing conventional cardiovascular factors to carotid ultrasound image phenotypes: a Japanese diabetes cohort study. *Echocardiography.* 2019;36:345–61.
  90. Maniruzzaman M, Rahman MJ, Al-MehediHasan M, et al. Accurate diabetes risk stratification using machine learning: role of missing value and outliers. *J Med Syst.* 2018;42(5):92.
  91. Maniruzzaman M, Kumar N, Menhazul Abedin M, et al. Comparative approaches for classification of diabetes mellitus data: machine learning paradigm. *Comput Methods Prog Biomed.* 2017;152:23–34.
  92. Araki T, Ikeda N, Shukla D, et al. A new method for IVUS-based coronary artery disease risk stratification: a link between coronary & carotid ultrasound plaque burdens. *Comput Methods Prog Biomed.* 2016;124:161–79.
  93. Al'Aref SJ, Anchouche K, Singh G, et al: Clinical applications of machine learning in cardiovascular disease and its relevance to cardiac imaging. *Eur Heart J* 2018
  94. Chou C-L, Wu Y-J, Hung C-L, et al. Segment-specific prevalence of carotid artery plaque and stenosis in middle-aged adults and elders in Taiwan: a community-based study. *J Formos Med Assoc.* 2019;118(1):64–71.
  95. Farkas S, Molnár S, Nagy K, Hortobágyi T, Csiba L. Comparative in vivo and in vitro postmortem ultrasound assessment of intima-media thickness with additional histological analysis in human carotid arteries. *Perspect Med.* 2012;1(1):170–6.
  96. Gamble G, Beaumont B, Smith H, et al. B-mode ultrasound images of the carotid artery wall: correlation of ultrasound with histological measurements. *Atherosclerosis.* 1993;102(2):163–73.
  97. Cortes C, Vapnik V. Support-vector networks. *Mach Learn.* 1995;20(3):273–97.
  98. Dalbeni A, Giollo A, Tagetti A, et al. Traditional cardiovascular risk factors or inflammation: which factors accelerate atherosclerosis in arthritis patients? *Int J Cardiol.* 2017;236:488–92.
  99. Acharya UR, Sree SV, Molinari F, Saba L, Nicolaides A, Suri JS. An automated technique for carotid far wall classification using grayscale features and wall thickness variability. *J Clin Ultrasound.* 2015;43(5):302–11.
  100. Kyriacou EC, Petroudi S, Pattichis CS, et al. Prediction of high-risk asymptomatic carotid plaques based on ultrasonic image features. *IEEE Trans Inf Technol Biomed.* 2012;16(5):966–73.
  101. Gastouniotti A, Makrodimitris S, Golemati S, Kadoglou NP, Liapis CD, Nikita KS. A novel computerized tool to stratify risk in carotid atherosclerosis using kinematic features of the arterial wall. *IEEE J Biomed Health Inform.* 2015;19(3):1137–45.
  102. Hu X, Reaven PD, Saremi A, et al. Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance. *EURASIP J Bioinforma Syst Biol.* 2016;2016(1):14.
  103. Narain R, Saxena S, Goyal AK. Cardiovascular risk prediction: a comparative study of Framingham and quantum neural network based approach. *Patient Prefer Adherence.* 2016;10:1259–70.
  104. Unnikrishnan P, Kumar DK, Poosapadi Arjunan S, Kumar H, Mitchell P, Kawasaki R. Development of health parameter model for risk prediction of CVD using SVM. *Comput Math Meth Med.* 2016;2016:1–7.
  105. Zarkogianni K, Athanasiou M, Thanopoulou AC, Nikita KS. Comparison of machine learning approaches toward assessing the risk of developing cardiovascular disease as a long-term diabetes complication. *IEEE J Biomed Health Inform.* 2018;22(5):1637–47.
  106. Saba L, Jain PK, Suri HS, et al. Plaque tissue morphology-based stroke risk stratification using carotid ultrasound: a polling-based PCA learning paradigm. *J Med Syst.* 2017;41(6):98.
  107. Motwani M, Dey D, Berman DS, et al. Machine learning for prediction of all-cause mortality in patients with suspected coronary artery disease: a 5-year multicentre prospective registry analysis. *Eur Heart J.* 2017;38(7):500–7.
  108. Korshunov VA, Schwartz SM, Berk BC. Vascular remodeling: hemodynamic and biochemical mechanisms underlying Glagov's phenomenon. *Arterioscler Thromb Vasc Biol.* 2007;27(8):1722–8.
  109. Leskinen Y, Lehtimäki T, Loimaala A, et al. Carotid atherosclerosis in chronic renal failure—the central role of increased plaque burden. *Atherosclerosis.* 2003;171(2):295–302.
  110. Razzouk L, Rockman CB, Patel MR, et al. Co-existence of vascular disease in different arterial beds: peripheral artery disease and carotid artery stenosis—data from Life Line Screening®. *Atherosclerosis.* 2015;241(2):687–91.
  111. Banerjee C, Chimowitz MI. Stroke caused by atherosclerosis of the major intracranial arteries. *J Vasc Surg.* 2017;65(6):1864–5.

112. Chen PC, Jeng JS, Hsu HC, Su TC, Chien KL, Lee YT. Carotid atherosclerosis progression and risk of cardiovascular events in a community in Taiwan. *Sci Rep*. 2016;6:25733.
113. Cuadrado-Godia E, Srivastava SK, Saba L, *et al*: Geometric total plaque area is an equally powerful phenotype compared with carotid intima-media thickness for stroke risk assessment: a deep learning approach. *J Vasc Ultrasound* 2018. 1544316718806421.
114. Beach KW: Principles of ultrasonic imaging and instrumentation. In: *Ultrasound and carotid bifurcation atherosclerosis*. Edited by Nicolaides A, Beach KW, Kyriacou E, Pattichis CS. London: Springer; 2012: 67–96.
115. Gupta A, Kesavabhotla K, Baradaran H, *et al*. Plaque echolucency and stroke risk in asymptomatic carotid stenosis: a systematic review and meta-analysis. *Stroke*. 2015;46(1):91–7.
116. Huijbers A, de Borst GJ, Bulbulia R, Pan H, Halliday A. Plaque echolucency and the risk of ischaemic stroke in patients with asymptomatic carotid stenosis within the first Asymptomatic Carotid Surgery Trial (ACST-1). *Eur J Vasc Endovasc Surg*. 2016;51(5):616–21.
117. Kotsis V, Jamthikar AD, Araki T, *et al*. Echolucency-based phenotype in carotid atherosclerosis disease for risk stratification of diabetes patients. *Diabetes Res Clin Pract*. 2018;143:322–31.
118. Park TH. Evaluation of carotid plaque using ultrasound imaging. *J Cardiovasc Ultrasound*. 2016;24(2):91–5.
119. Picano E, Paterni M. Ultrasound tissue characterization of vulnerable atherosclerotic plaque. *Int J Mol Sci*. 2015;16(5):10121–33.
120. Nicolaides AN, Kakkos SK, Kyriacou E, *et al*. Asymptomatic internal carotid artery stenosis and cerebrovascular risk stratification. *J Vasc Surg*. 2010;52(6):1486–1496.e1485.
121. Pedro LM, Sanches JM, Seabra J, Suri JS, Fernandes e Fernandes J. Asymptomatic carotid disease—a new tool for assessing neurological risk. *Echocardiography*. 2014;31(3):353–61.
122. Pahan K. Lipid-lowering drugs. *Cell Mol Life Sci*. 2006;63(10):1165–78.
123. Abramowicz M, Zuccotti G, Pflomm J-M. Metformin for prediabetes (reprinted from *The medical letters on drugs and therapeutics*, vol 58, pg 141, 2016). *JAMA*. 2017;317(11):1171–1.
124. LeCun Y, Bengio Y, Hinton G. Deep learning. *Nature*. 2015;521:436–44.
125. Litjens G, Kooi T, Bejnordi BE, *et al*. A survey on deep learning in medical image analysis. *Med Image Anal*. 2017;42:60–88.
126. Shen D, Wu G, Suk H-I. Deep learning in medical image analysis. *Annu Rev Biomed Eng*. 2017;19:221–48.
127. • Lekadir K, Galimzianova A, Betriu À, *et al*. A convolutional neural network for automatic characterization of plaque composition in carotid ultrasound. *IEEE J Biomed Health Inform*. 2017;21(1):48–55 **This was an important study that performed the carotid atherosclerotic plaque characterization using DL approach.**
128. Zreik M, van Hamersvelt RW, Wolterink JM, Leiner T, Viergever MA, Išgum I. A recurrent CNN for automatic detection and classification of coronary artery plaque and stenosis in coronary CT angiography. *IEEE Trans Med Imaging*. 2018:1.
129. Can we open the black box of AI? [<https://www.nature.com/news/can-we-open-the-black-box-of-ai-1.20731>]. Accessed 1 Oct 2018.
130. Henglin M, Stein G, Hushcha PV, Snoek J, Wiltschko AB, Cheng S. Machine learning approaches in cardiovascular imaging. *Circ Cardiovasc Imaging*. 2017;10(10):e005614.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.